I am a medical oncologist who specializes in treating women with gynecologic cancers (ovarian, uterine, endometrial, and cervical cancer).
The gynecologic medical oncology group at Memorial Sloan Kettering works in coordination with our gynecologic surgeons and radiation oncologists to determine the best treatment plans for our patients. We work to improve care not only by using standard therapies, but by offering participation in ongoing clinical trials that incorporate promising new medications for treating cancer.
My clinical research is focused on new therapies for ovarian cancer. In particular, I am interested in the development of PARP inhibitor therapy for ovarian cancer and how best to combine this new class of agents with standard therapies.
Along with many of my colleagues at Memorial Sloan Kettering, I am an active participant in the Gynecologic Oncology Group (GOG) — a national clinical research group that works to improve the care of women with gynecologic malignancies. I am a member of the GOG’s Phase I committee as well as the Experimental Medicine committee. Also with the GOG, I serve as the national principle investigator of phase I trials incorporating new biologic therapies into treatment for ovarian cancer.
- Clinical Expertise: Gynecologic Malignancies
- Languages Spoken: English
- Education: MD, PhD, The Johns Hopkins School of Medicine
- Residencies: The Johns Hopkins Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Katherine M. Bell-McGuinn
- A Phase I Study of BKM120 and Olaparib in Patients with High-Grade Serous Ovarian Cancer
- A Phase I Study of Carboplatin/Paclitaxel/Bevacizumab and ABT-888 in Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- A Phase II Study of Rucaparib in Patients Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- A Phase III Study of Carboplatin/Paclitaxel with or without Veliparib in Women with Previously Untreated Stage III/IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- A Phase III Study of Rucaparib after Platinum-Based Chemotherapy in Women with High-Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more